Plas Lab Eyes a New Glioma Target with $100k Grant

Share

Dr. David Plas at UC’s Vontz Center for Molecular Studies. Cindy Starr photo.

David Plas, PhD, Associate Professor of Cancer Biology at the University of Cincinnati College of Medicine, brings a fresh viewpoint and the mindset of a leukemia researcher to the problem of glioma, a stubbornly aggressive form of brain cancer. He notes that while leukemias are treated more successfully than ever before, “gliomas could stand some major improvements.”

Dr. Plas is among a cadre of researchers at the UC Cancer Institute whose expertise is being tapped by the UC Brain Tumor Center, which straddles both the Cancer Institute and the UC Neuroscience Institute. Together these talented researchers are homing in on the molecular profile of glioma, a cancer that develops from glial cells in the brain and whose most common form is glioblastoma multiforme.  An estimated 13,000 Americans die of brain and other nervous system cancers each year.

“In order to bring personalized therapy to brain cancers, it is necessary to develop new drugs that target the major pathways used by cancer genes,” Dr. Plas says. “Unfortunately, this approach has not yet been successful in brain cancer. We hope to bring some of the ideas from the world of leukemia research into brain cancer and see whether they can be successfully applied or modified.”

Armed with a $100,000 pilot grant funded locally and awarded by the UC Brain Tumor Center’s Molecular Therapeutics Program, a translational research program that leads to Phase I clinical trials, Dr. Plas and his laboratory team are focused on a protein known as S6Kinase1, or S6K1. The protein is in a pathway downstream of another protein, PTEN, a major tumor suppressor that is frequently mutated in glioma. The deficiency of PTEN occurs in all four molecular subtypes of glioblastoma.

Dr. Plas and his laboratory team have assembled a panel of five pre-clinical compounds through collaboration with chemists from the pharmaceutical industry as well as leading academic chemists. Using these compounds, they are performing the first comprehensive analysis of S6K1 as a target for brain cancer therapy.

“This work will provide the critical first step for a new direction in the development of new drugs for personalized cancer therapy of brain cancer,” Dr. Plas says.

Dr. Plas notes that S6K1 is a type of kinase – a protein that modifies other proteins – that has not yet been targeted. “We’ve only recently become able to target S6K1,” he says. “We are hoping to be on the front wave of targeting this pathway toward the development of S6K1 inhibitors.”

Work in the Plas Lab fits into a larger picture of innovative laboratories at UC that are developing molecule-targeted therapies for glioblastoma. The laboratories of El Mustapha Bahassi, PhD, and James Driscoll, MD, PhD, for example, are focusing on mutations on the epidermal growth factor receptor (EGFR). In glioblastoma, EGFR can lead to faulty signaling or “overactivation,” which causes cells to multiply too rapidly and to result in cancer. At least 30 to 50 percent of glioblastoma cases involve a malfunction of the EGF receptor. Dr. Plas notes that, “EGFR actually controls many different pathways. One of those pathways leads to S6Kinase1. So you can say that our work is related because these pathways are often interconnected.”

Dr. Plas says that one can visualize cancer from a genomic view (according to chromosomes or genes) or from a pathway view (according to molecular interactions). Metaphorically, one might imagine the chromosomes as busy airports and the pathways as the flights that go between them.

Dr. Plas is clearly excited about the developments. “We have an opportunity to use targeted therapeutics that have not been successfully applied in glioma therapy,” he says. “What draws our interest is the importance of the problem.”

 

– Cindy Starr

This entry was posted in UCNI Weekly Blog. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • UCNI Weekly Blog
  • Hope Stories

    • Dr. Mike’s Story: Glioblastoma

      Dr. Mike's Story: Glioblastoma Sixteen months after receiving a diagnosis of brain cancer, Dr. Michael Wood continues to attack his disease with wellness. In addition to surgery, radiation, chemotherapy and strong family support, the 61-year-old Cincinnati otolaryngologist has worked hard to provide his own...
    • Jim’s Story: Pituitary Tumor

      Jim's Story: Pituitary Tumor One turn of events led to another, and so it was that Jim, and not his wife, took Jim’s 87-year-old father to his appointment with the dermatologist for the first time. And so it was that the dermatologist was not...
    • Bob’s Story: Glioblastoma

      Bob's Story: Glioblastoma Bob’s story blends coincidence with collaboration and hope. The coincidence involves the 62-year-old West Chester man’s best buddy, “Jake,” a 165-pound...
    • Joe’s Story: Oligodendroglioma

      Joe's Story: Oligodendroglioma Joe calls it a miracle and a gift from “a higher power.” Others might call it a fortuitous turn of fate. Either way, Joe’s experience embodies a reversal of fortune that is both wonderful and startling. Once a man with...
    • Blake’s Story: Medulloblastoma

      Blake's Story: Medulloblastoma Blake knew he was in the right hands the moment he saw the surgeon’s wrists. Dr. John M. Tew, Blake’s neurosurgeon, was wearing one of Lance Armstrong’s yellow LiveStrong cancer bracelets. So was Blake. Dr. Tew, who was also sporting...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Sandra’s Story Glioma

      Sandra's Story Glioma Sandra (Sandy) is a smiling, breathing reminder that hope exists for patients with even the most challenging type of brain tumors. Nine years ago, when Sandy was first told that she had six months to live, she stared back blankly...
    • Doc’s Story: Metastatic Brain Tumors

      Doc’s Story: Metastatic Brain Tumors First there were headaches. Bad ones. Migraines, probably. Then, one day in mid-May, 2010, his knee, foot and arm went numb on his left side. Darrell “Doc” Rodgers, the 700WLW radio personality, feared he was having a stroke. In the emergency...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain Metastasis Semiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Kim’s Story: Brain Metastasis

      Kim's Story: Brain Metastasis In a poem she wrote for her creative writing class, Stephanie remembered it as the time when “cancer was fighting back just as hard as my mom was fighting it off.” Stephanie’s mother, Kim, was in her third battle with cancer. Kim...
    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Kevin’s Story: Acoustic Neuroma

      Kevin's Story: Acoustic Neuroma Kevin was in his mid-40s when he began to notice that he wasn’t hearing quite as well as in the past. But the change was gradual, so he didn’t worry about it. A few years went by, and the hearing...
    • John’s Story: Glioblastoma

      John's Story: Glioblastoma John, a retired painter and carpenter, is a tall, solidly built man with a strong inclination toward getting things done. A former Vista volunteer who was equally comfortable running a food co-op in an underserved neighborhood or standing near the...